Other Assets

CASI’s assets include a small portfolio of FDA-approved and FDA-pending ANDAs for generic products.

For the treatment of chronic hepatitis B virus infections

Product	Approved
Entecavir tablets	X
Tenofovir disoproxil fumarate (TDF) tablets	X

Product	Approved
Benazepril tablets	X
Bisoprolol fumarate tablets	X
Burprenorphine HCL Sublingual tablets	X
Cefprozil tablets	X
Cilostazol tablets – 50mg	X
Cilostazol tablets – 100mg	X
Desvenlafaxine ER tablets	X
Diclofenac potassium 50mg tablets	X
Diclofenac sodium DR 25mg, 50mg tablets	X
Diclofenac sodium DR 75mg tablets	X
Heparin sodium for injection	X
Methimazole tablets	X
Nabumetone tablets	X
Ondansetron HCL tablets	X
Repaglinide tablets	X
Tizanidine tablets	X

Product	Pending
Aripiprazole tablets	X
Bepotastine Ophthalmic Solution	X
Bromfenac Ophthalmic Solution	X
Telmisartan and hydrochlorothiazide tablets	X

About Us

CASI is a U.S. NASDAQ-listed biopharmaceutical company with a platform to develop and accelerate the launch of pharmaceutical products and innovative therapeutics in China, the U.S., and throughout the world. We have offices in Rockville, Maryland, and a wholly owned subsidiary in Beijing, China, through which substantially all of our operations are conducted.

Downloads

Corporate Presentation